Baguinda, Mark Daniel A.

HRN: 28-62-91  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/28/2026
CEFUROXIME 750MG (VIAL)
02/28/2026
03/07/2026
IV
430MG
Q8
PCAP C
Pending Pharmacy Acceptance 

 Indication:  Empiric    Type of Infection:  Pneumonia    Compliance to guidelines: